Compositions and methods for treatment of disorders related to CEP290

Patent metadata

Field	Value
Publication number	US-10301366-B2
Application number	US-201816180892-A
Country	US
Kind code	B2
Filing date	Nov 5, 2018
Priority date	Jul 16, 2013
Publication date	May 28, 2019
Grant date	May 28, 2019

Abstract

Compositions are provided that comprise a recombinant vector carrying a nucleic acid sequence encoding a fragment of CEP290 lacking all or part of its N-terminal and C-terminal inhibitory regions, under the control of regulatory sequences which express the product of said gene in a selected cell of a mammalian subject, and a pharmaceutically acceptable carrier. These and other compositions are disclosed with are useful in methods for treating a mammalian subject having a disease associated with a CEP290 mutation, such as Lebers Congenital Amaurosis.

First claim

The invention claimed is:

1. A method of treating a mammalian subject having a disease associated with a defect in the CEP290 gene, a CEP290 mutation, or a defect in the expression or levels of expression of the CEP290 protein, the method comprising administering to said subject an effective concentration of a composition comprising:
(i) a synthetic or recombinant nucleic acid sequence encoding a truncated CEP290 protein comprising discontinuous CEP290 fragments spliced together in a single open reading frame, said truncated CEP290 protein having biological activity that mimics the biological activity of normal full-length CEP290, wherein the truncated CEP290 protein comprises the amino acid sequence of SEQ ID NO: 6; and
(ii) a therapeutically acceptable or pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein the administering comprises delivering the composition by subretinal injection to the retina or photoreceptor cells, delivering the composition by retrograde urethral injection to the kidney, delivering the composition by intra-ventricular or intra-cerebral injection to the brain, or topically delivering the composition to nasal epithelium.

3. The method of claim 1 , wherein the mammalian subject is a human.

4. A method of treating a mammalian subject having a disease associated with a defect in the CEP290 gene, a CEP290 mutation, or a defect in the expression or levels of expression of the CEP290 protein, the method comprising administering to said subject an effective concentration of a composition comprising:
(i) a synthetic or recombinant nucleic acid sequence encoding a truncated CEP290 protein comprising discontinuous CEP290 fragments spliced together in a single open reading frame, said truncated CEP290 protein having biological activity that mimics the biological activity of normal full-length CEP290, wherein the nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 5; and
(ii) a therapeutically acceptable or pharmaceutically acceptable carrier.

5. The method of claim 4 , wherein the administering comprises delivering the composition by subretinal injection to the retina or photoreceptor cells, delivering the composition by retrograde urethral injection to the kidney, delivering the composition by intra-ventricular or intra-cerebral injection to the brain, or topically delivering the composition to nasal epithelium.

6. The method of claim 4 , wherein the mammalian subject is a human.

7. A method of treating a mammalian subject having a disease associated with a defect in the CEP290 gene, a CEP290 mutation, or a defect in the expression or levels of expression of the CEP290 protein, the method comprising administering to said subject an effective concentration of a composition comprising:
(i) a synthetic or recombinant nucleic acid sequence encoding a truncated CEP290 protein comprising discontinuous CEP290 fragments spliced together in a single open reading frame, said truncated CEP290 protein having biological activity that mimics the biological activity of normal full-length CEP290, wherein the discontinuous CEP290 fragments comprise the amino acid sequence of SEQ ID NO: 49 and the amino acid sequence of SEQ ID NO: 53; and
(ii) a therapeutically acceptable or pharmaceutically acceptable carrier.

8. The method of claim 7 , wherein the administering comprises delivering the composition by subretinal injection to the retina or photoreceptor cells.

9. The method of claim 7 , wherein the administering comprises delivering the composition by retrograde urethral injection to the kidney.

10. The method of claim 7 , wherein the administering comprises delivering the composition by intra-ventricular or intra-cerebral injection to the brain.

11. The method of claim 7 , wherein the administering comprises topically delivering the composition to nasal epithelium.

12. The method of claim 7 , wherein the discontinuous CEP290 fragments further comprise the amino acid sequence of SEQ ID NO: 51.

13. The method of claim 7 , wherein the discontinuous CEP290 fragments further comprise the amino acid sequence of SEQ ID NO: 52.

14. The method of claim 7 , wherein the discontinuous CEP290 fragments further comprise the amino acid sequence of SEQ ID NO: 51 and the amino acid sequence of SEQ ID NO: 52.

15. The method of claim 7 , wherein the mammalian subject is a human.

16. The method of claim 7 , wherein the mammalian subject has shown a clinical sign of ciliopathy.

17. The method of claim 7 , wherein the mammalian subject has Lebers Congenital Amaurosis (LCA).

18. The method of claim 16 , wherein the clinical sign comprises decreased peripheral vision, decreased central vision, decreased night vision, loss of color perception, reduction in visual acuity, decreased photoreceptor function, or a pigmentary change.

19. The method of claim 16 , wherein the ciliopathy is a disorder of the bone, brain, central nervous system, kidney, or olfactory epithelia.

Assignees

• Univ Pennsylvania

Inventors

• Drivas Theodore G
• Bennett Jean

Classifications

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• A61K48/00

  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title

• C07K14/47 Primary

  from mammals · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title